A Conjecture or Two
None of the following is to be regarded by anyone as either good investment advice, nor a depiction of what will happen in the future with Anavex 2-73. It is merely a conjecture; based upon existing, albeit incomplete or not fully developed or released information.
Two significant facts (not conjectures) have just been posted. Anavex 2-73, for a 41-week dosing period, at doses ranging from 10 to 50 mgs, produces no appreciable or disqualifying side effects. None of the patients in the 41-week dosing period elected or were forced out because of side effects. For neurological drugs, that is remarkable.
Secondly, and extremely important, the drug simply stopped the progression of Alzheimer’s symptoms during the entire 41-week study period. Nothing else has been shown to do this.
From all of that, here are my conjectures.
After 2-73 gains FDA approval for Alzheimer’s patients, it becomes widely prescribed, both for early-stage presentations, where it will prevent progression to later debilitating stages, and also to those with more advanced symptoms, where, as in this present study, symptomatic progression is terminated.
All well and good, both for Anavex and for patients. Here, then, is the greater conjecture.
Because of 2-73's safety, lack of side effects, and probably as a result of new studies, it becomes prescribed as the preferred treatment for Parkinson’s, amyotrophic lateral sclerosis (Lou Gerhig’s Disease), and perhaps other geriatric neurodegenerative diseases.
If any of this occurs (quite likely, I think), it will revolutionize modern medicine, to the degree or greater than antibiotics did in the late 40's and early 50's.
But here’s a panoptic conjecture. It soon becomes apparent that 2-73 should simply be prescribed, prophylactically (solely for prevention), for everyone at the age of 50. Just as so many now take statins to prevent heart disease, many, many more (well, everyone) could take a daily 10mg of Anavex 2-73 to prevent the onset of Alzheimer’s, ALS, Parkinson’s and who know what other diseases afflicting people in the last half of their lives.
Then, when millions are taking preventative doses of 2-73, for the diseases for which it is known or presumed to be efficacious or preventative, this might be discovered. Presently, there are fragmentary indications that 2-73 prevents or treats various cardiovascular conditions, and perhaps, even forms of cancer.
What happens if it is discovered that those taking 2-73 chronically simply have reduced or absent other diseases, without side effects? Prescribe it then for everyone.
Others can conjecture on the revenue streams chronic administration of 2-73 to virtually everyone at the age of 50 or so would generate.
Now, is there any legitimate biological basis for these conjectures, particularly 2-73's prevention of a multitude of geriatric diseases? Very much. Uniquely, 2-73 restores the connection and mutual, normal function of mitochondria and endoplasmic reticula. Mitochondria synthesize adenosine triphosphate, ATP, the energy source for most cellular reactions. Endoplasmic reticula, when attached to the mitochondria, use the ATP’s energy to properly fold genetically-directed proteins into precise, folded structures; in most cases reaction-controlling enzymes. Mis-folded proteins; poorly-functioning enzymes, cannot efficiently and completely control and promote cellular chemical reactions. Hence, disease. The tertiary, 3-D structure of enzymes is intensely studied. Mis-folded enzyme proteins simply fail to properly promote or control cellular chemistry. Disease or death results. Anavex 2-73 restores a more youthful, full-functioning mitochondrion-endoplasmic reticulum arrangement. Fully functioning enzymes can then be synthesized, with proper cellular health restored.
Lets’ watch and see what happens.
